|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Kim WY and Kaelin WG: Role of VHL gene
mutation in human cancer. J Clin Oncol. 22:4991–5004. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Latif F, Tory K, Gnarra J, Yao M, Duh FM,
Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al:
Identification of the von Hippel-Lindau disease tumor suppressor
gene. Science. 260:1317–1320. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Clark PE: The role of VHL in clear-cell
renal cell carcinoma and its relation to targeted therapy. Kidney
Int. 76:939–945. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Arjumand W and Sultana S: Role of VHL gene
mutation in human renal cell carcinoma. Tumour Biol. 33:9–16. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Li B, Qiu B, Lee DS, Walton ZE, Ochocki
JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I and Simon MC:
Fructose-1,6-bisphosphatase opposes renal carcinoma progression.
Nature. 513:251–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Elmore JM, Kadesky KT, Koeneman KS and
Sagalowsky AI: Reassessment of the 1997 TNM classification system
for renal cell carcinoma. Cancer. 98:2329–2334. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hong SK, Jeong CW, Park JH, Kim HS, Kwak
C, Choe G, Kim HH and Lee SE: Application of simplified Fuhrman
grading system in clear-cell renal cell carcinoma. BJU Int.
107:409–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chen M, Zhang J, Li N, Qian Z, Zhu M, Li
Q, Zheng J, Wang X and Shi G: Promoter hypermethylation mediated
downregulation of FBP1 in human hepatocellular carcinoma and colon
cancer. PloS One. 6:e255642011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Dong C, Yuan T, Wu Y, Wang Y, Fan TW,
Miriyala S, Lin Y, Yao J, Shi J, Kang T, et al: Loss of FBP1 by
Snail-mediated repression provides metabolic advantages in
basal-like breast cancer. Cancer Cell. 23:316–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Liu X, Wang X, Zhang J, Lam EK, Shin VY,
Cheng AS, Yu J, Chan FK, Sung JJ and Jin HC: Warburg effect
revisited: An epigenetic link between glycolysis and gastric
carcinogenesis. Oncogene. 29:442–450. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Alderton GK: Tumorigenesis: FBP1 is
suppressed in kidney tumours. Nat Rev Cancer. 14:5752014.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Phillips R: Kidney cancer: FBP1 depletion
feeds ccRCC. Nat Rev Urol. 11:4822014. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Giatromanolaki A, Sivridis E, Kouskoukis
C, Gatter KC, Harris AL and Koukourakis MI: Hypoxia-inducible
factors 1alpha and 2alpha are related to vascular endothelial
growth factor expression and a poorer prognosis in nodular
malignant melanomas of the skin. Melanoma Res. 13:493–501. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Theodoropoulos VE, Lazaris A, Sofras F,
Gerzelis I, Tsoukala V, Ghikonti I, Manikas K and Kastriotis I:
Hypoxia-inducible factor 1 alpha expression correlates with
angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol.
46:200–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Helczynska K, Larsson AM, Mengelbier
Holmquist L, Bridges E, Fredlund E, Borgquist S, Landberg G,
Påhlman S and Jirström K: Hypoxia-inducible factor-2alpha
correlates to distant recurrence and poor outcome in invasive
breast cancer. Cancer Res. 68:9212–9220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011.PubMed/NCBI
|
|
18.
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Morais C, Johnson DW, Vesey DA and Gobe
GC: Functional significance of erythropoietin in renal cell
carcinoma. BMC Cancer. 13:142013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Abhold E, Rahimy E, Wang-Rodriguez J,
Blair KJ, Yu MA, Brumund KT, Weisman RA and Ongkeko WM: Recombinant
human erythropoietin promotes the acquisition of a malignant
phenotype in head and neck squamous cell carcinoma cell lines in
vitro. BMC Res Notes. 4:5532011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Phillips TM, Kim K, Vlashi E, McBride WH
and Pajonk F: Effects of recombinant erythropoietin on breast
cancer-initiating cells. Neoplasia. 9:1122–1129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhou B, Damrauer JS, Bailey ST, Hadzic T,
Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, et al:
Erythropoietin promotes breast tumorigenesis through
tumor-initiating cell self-renewal. The Journal of clinical
investigation. 124:553–563. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Rankin EB, Biju MP, Liu Q, Unger TL, Rha
J, Johnson RS, Simon MC, Keith B and Haase VH: Hypoxia-inducible
factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin
Invest. 117:1068–1077. 2007. View
Article : Google Scholar : PubMed/NCBI
|
